Scholarlink

Background <p>Glycosylation, as one of the most prevalent forms of post-translational modification, plays a pivotal role in tumor progression through structural alterations of serum N-glycans in hepatocellular carcinoma (HCC). In this study, we systematically investigated these N-glycan profiles as potential prognostic biomarkers for predicting patient survival outcomes.</p> Methods <p>This study enrolled a cohort of 150 hepatitis B virus (HBV)-related HCC patients (BCLC stages A-D) who received treatment and follow-up monitoring at Southwest Medical University Hospital from 2022 to 2023. Additionally, 105 chronic hepatitis B (CHB) patients, 50 healthy individuals matched for age and gender were recruited as controls. Serum N-glycan profiles were characterized using capillary gel electrophoresis laser-induced fluorescence detection (CGE-LIF).</p> Results <p>The relative intensities (RIs) of Peak 9 (NA3Fb) was specifically elevated in HBV-related HCC patients. This peak emerged as an independent predictor of survival (<i>p</i> = 0.004), strongly correlated with advanced tumor stage (<i>p</i> &lt; 0.01), and it was associated with HBsAg loss following anti-PD-1 therapy. MGAT4A, the gene implicated in regulating Peak 9, is likely significantly involved in critical pathways driving HCC progression.</p> Conclusions <p>Serum N-glycan profiling represents a promising noninvasive tool for monitoring prognosis and outcomes in HCC patients. Peak 9 (NA3Fb) was identified as a prognostic biomarker significantly associated with clinical outcomes in HBV-related HCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Serum N-glycan NA3Fb identified as a prognostic biomarker of poor outcome in HBV-related hepatocellular carcinoma

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月20日

查看全文
  • Pengyuan Kang,
  • Min Wang,
  • Jie Liu,
  • Jiang Wang,
  • Xinjie Li,
  • Bo Jiang,
  • Rui Lin,
  • Siqi Zhong,
  • Lei Xu,
  • Cuiying Chen,
  • Bo Li,
  • Tao Shen

摘要

Background

Glycosylation, as one of the most prevalent forms of post-translational modification, plays a pivotal role in tumor progression through structural alterations of serum N-glycans in hepatocellular carcinoma (HCC). In this study, we systematically investigated these N-glycan profiles as potential prognostic biomarkers for predicting patient survival outcomes.

Methods

This study enrolled a cohort of 150 hepatitis B virus (HBV)-related HCC patients (BCLC stages A-D) who received treatment and follow-up monitoring at Southwest Medical University Hospital from 2022 to 2023. Additionally, 105 chronic hepatitis B (CHB) patients, 50 healthy individuals matched for age and gender were recruited as controls. Serum N-glycan profiles were characterized using capillary gel electrophoresis laser-induced fluorescence detection (CGE-LIF).

Results

The relative intensities (RIs) of Peak 9 (NA3Fb) was specifically elevated in HBV-related HCC patients. This peak emerged as an independent predictor of survival (p = 0.004), strongly correlated with advanced tumor stage (p < 0.01), and it was associated with HBsAg loss following anti-PD-1 therapy. MGAT4A, the gene implicated in regulating Peak 9, is likely significantly involved in critical pathways driving HCC progression.

Conclusions

Serum N-glycan profiling represents a promising noninvasive tool for monitoring prognosis and outcomes in HCC patients. Peak 9 (NA3Fb) was identified as a prognostic biomarker significantly associated with clinical outcomes in HBV-related HCC.